Celldex redeems monoclonal antibody pair phase 3 wins chronic skin condition

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.

science

Sources

• T2Celldex redeems monoclonal antibody pair phase 3 wins chronic skin conditionFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07